UNSPSC 51432314: Moxonidine hydrochloride

This classification denotes an antihypertensive agent with the molecular formula C9H12ClN5O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5RYW07SK5E, chemically known as 4-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamine hydrochloride, but more generally known as moxonidine hydrochloride, which bears US NIH Compound Identifier 156339. European Medicines Agency schedules moxonidine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09092MIG.

Most nations, for tariff purposes, schedule moxonidine hydrochloride under HS 29335995. SMILES: CC1NC(C(C(N1)CL)NC2=NCCN2)OC.CL.

UNSPSC 51432314 Moxonidine hydrochloride is a Commodity code covering a specific pharmaceutical active ingredient used in antihypertensive medications, but recent state and local solicitations tagged with this code do not reflect procurement of moxonidine itself. Instead, the code appears in opportunities soliciting broader advanced life support medications and generic multi-source pharmaceuticals where moxonidine may be a component of formulated products rather than a standalone procurement target. State and local buyers under this code family include city fire-rescue departments, state health agencies, and cooperative purchasing alliances serving multi-state and multi-jurisdictional government facilities. The work being solicited spans sealed-bid purchases of specific medication line items for emergency medical services, exploratory requests for information on direct-to-manufacturer pharmaceutical procurement models, and master-supply agreements for generic and over-the-counter pharmaceutical products distributed through authorized wholesalers to government healthcare and emergency-response settings.

Recent activity shows geographic spread across Florida, Texas, and the Upper Midwest. The City of Tampa's Purchasing Department issued IFB No. 26P00188 on April 24, 2026, seeking Advanced Life Support Medications for Tampa Fire Rescue with a due date of April 8, 2026 and an estimated contract value of $40,000.00; the solicitation specified firm pricing including shipping, nine-month minimum expiration dates, and a one-year base term with two optional renewals plus three 30-day extensions, with a Small Local Business Enterprise sheltered market designation offering a 5 percent bid discount. The Texas Health and Human Services Commission posted RFI No. HHS0017013 on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP on January 20, 2026, with a March 26, 2026 due date for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon through three authorized wholesalers, with weighted evaluation placing 75 percent on price competitiveness and a two-year contract term with optional extensions through June 30, 2028.